Marcus Monroe, MD
Otolaryngology · Portland, ORNPI 1376704692
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,071 of the $15,895 with a category attached, or 94.8%. 4 manufacturers reported payments, led by Sanofi at 49.5% of the total. Reporting peaked in 2019 at $7,935 and has fallen 96.2% since, to $305 in 2023. Among otolaryngology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $1059.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$8K
- Merck$4K
- Regeneron$2K
- Regeneron Healthcare Solutions, Inc.$2K
Across 60 payments — averaging $36,167 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.1M
- GSK$51K
What the payments were for
- Consulting fees$15,07195%
- Travel & lodging$4993%
- Food & beverage$3252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 8 | $7,865 |
| Merck | 4 | $3,680 |
| Regeneron | 1 | $2,400 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,950 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,895 in reported general payments places this provider in the 95th percentile of 128 otolaryngology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 15 | $284 |
| Oxycodone Hcl | 17 | $118 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Portland
- Mathew GeltzeilerPortland$221K
- Ryan LiPortland$160K
- Jeremiah AltPortland$89K
- Mark WaxPortland$20K
- Joshua SchindlerPortland$8K
- Daniel ClayburghPortland$7K
- Timothy HullarPortland$7K
- Paul FlintPortland$7K
- Justin HallPortland$4K
- Katie MelderPortland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.